Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly vs Every 3-week Ixabepilone in Metastatic Breast Cancer
NCT00593827Phase 2Completed
- Sponsor
- R-Pharm
- Start
- May 2008
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ixabepilone in breast cancer (2 arms), sponsored by R-Pharm. Primary endpoint: Progression-Free Survival at 6 Months. Started May 2008; status: completed.
02
Drugs
ixabepilone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00593827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00593827.